PT - JOURNAL ARTICLE AU - Rodriguez, Steven AU - Cao, Luxiang AU - Rickenbacher, Gregory T. AU - Benz, Eric G. AU - Magdamo, Colin AU - Gomez, Liliana Ramirez AU - Holbrook, Eric H. AU - Albers, Alefiya D. AU - Gallagher, Rose AU - Westover, M. Brandon AU - Evans, Kyle E. AU - Tatar, Daniel J. AU - Mukerji, Shibani AU - Zafonte, Ross AU - Boyer, Edward W AU - Yu, C. Ron AU - Albers, Mark W. TI - Innate immune signaling in the olfactory epithelium reduces odorant receptor levels: modeling transient smell loss in COVID-19 patients AID - 10.1101/2020.06.14.20131128 DP - 2020 Jan 01 TA - medRxiv PG - 2020.06.14.20131128 4099 - http://medrxiv.org/content/early/2020/06/16/2020.06.14.20131128.short 4100 - http://medrxiv.org/content/early/2020/06/16/2020.06.14.20131128.full AB - Post-infectious anosmias typically follow death of olfactory sensory neurons (OSNs) with a months-long recovery phase associated with parosmias. While profound anosmia is the leading symptom associated with COVID-19 infection, many patients regain olfactory function within days to weeks without distortions. Here, we demonstrate that sterile induction of anti-viral type I interferon signaling in the mouse olfactory epithelium is associated with diminished odor discrimination and reduced odor-evoked local field potentials. RNA levels of all class I, class II, and TAAR odorant receptors are markedly reduced in OSNs in a non-cell autonomous manner. We find that people infected with COVID-19 rate odors with lower intensities and have odor discrimination deficits relative to people that tested negative for COVID-19. Taken together, we propose that inflammatory-mediated loss of odorant receptor expression with preserved circuit integrity accounts for the profound anosmia and rapid recovery of olfactory function without parosmias caused by COVID-19.Competing Interest StatementDan Tatar is the founder of and holds equity in the ADK group. M.W.A. is an inventor on a patent application on the COVID Smell Test.Funding StatementThis work was supported by the NIH DP2 OD006662, the Harvard Blavatanik Sensory Disorder Fund, and the Wilkens Foundation (awarded to M.W.A.), R41 AG062130 (awarded to D.J.T.), a Harvard Catalyst PFDD Fellowship (awarded to S.R).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Mass General Brigham (formerly Partners) Institutional Review BoardAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data for this study is available with this submission, except raw clinical data with personal health information, or at Synapse (mouse RNA-seq data-syn22161010). https://www.synapse.org/#!Synapse:syn22161010